Coya rises after US FDA nod for ALS therapy mid-stage trial

Coya Therapeutics

25/08/2025 14:49

Updates

** Shares of Coya Therapeutics COYA.O rise as much as 6.2% to five-month high of $7.30

** U.S. FDA gives its go-ahead to the drugmaker to study its drug, COYA 302, as a potential treatment of amyotrophic lateral sclerosis (ALS) in a mid-stage study

** The acceptance of the Investigational New Drug application by the FDA triggers a $4.2 million milestone payment to Coya from Indian drugmaker Dr Reddy's Laboratories REDY.NS

** ALS, also known as Lou Gehrig's disease, is a rare neurological disease that affects the motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and eventually, death

** Including session's move, stock up 24.8% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))